Moderated by Precision's Kelly Wilder, EVP, Strategic Business Development, PRECISIONheor’s Jason Shafrin, PhD, and Meena Venkatachalam, MSc, discuss their recently published blog in Health Affairs
Adding to the ongoing national dialogue on racial inequality, PRECISIONheor’s Jason Shafin and Meena Venkatachalam join the conversation in their Health Affairs blog post: “Creating Incentives To Narrow The Gap In Health Outcomes: Expanding Value Assessment To Incorporate Health Inequality”.
ISPOR's “value flower” versus the traditional QALYs approach: Precision's Jason Shafrin, Kathy Lang and Ross Maclean discuss why the “value flower” model can more accurately value treatments - in cases like COVID-19 - which have a transformational impact on the lives of not only of patients, but also caregivers, employers, and broader society.
The Precision Value & Health family of brands is now Precision AQ
Precision AQ helps life sciences companies navigate the complexities of commercialization across a product’s lifecycle. Our team is comprised of experts, advisors, and creators working to ensure patients have access to life-changing medicines.
Our global offerings include:
Our name, which stands for Precision Access Quotient, reflects our approach to removing barriers – fusing together science (IQ, or Intelligence Quotient) and empathy (EQ, or Emotional Quotient). The result is “AQ: Access Quotient”, a critical ingredient in navigating the therapy-to-patient journey informed by data-driven analytics and insights.
To find out more about our global services and our unified mission, empowering access to life-changing medicines for all, visit: Precision AQ
